Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2018

Fair Value Disclosures [Abstract]

Schedule of Financial Instrument Measured on Recurring Basis

The valuation methodologies used for the Company’s financial instruments measured on a recurring basis at fair value, including the general classification of such instruments pursuant to the valuation hierarchy, is set forth in the tables below.

	As of December 31, 2018				Fair Value Measurements
	Carrying		Fair		As of December 31, 2018
	Amount		Value		Level 1		Level 2		Level 3
Liabilities:
Contingent consideration:
Asuragen	$	3,127	$	3,127	$	-	$	-	$	3,127
Other long-term liabilities:
Warrant liability		360		360		-		-		360
	$	3,487	$	3,487	$	-	$	-	$	3,487

	As of December 31, 2017				Fair Value Measurements
	Carrying		Fair		As of December 31, 2017
	Amount		Value		Level 1		Level 2		Level 3
Liabilities:
Contingent consideration:
Asuragen	$	1,581	$	1,581	$	-	$	-	$	1,581
Other long-term liabilities:
Warrant liability		473		473		-		-		473
	$	2,054	$	2,054	$	-	$	-	$	2,054

Schedule of Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation

								Cancellation		Adjustment
								of Obligation/		to Fair Value/
	December 31, 2017		Payments (1)			Accretion		Conversions Exercises		Mark to Market			December 31, 2018
Asuragen	$	1,581	$	(307	)	$	331	$	-	$	1,522		$	3,127
Underwriters Warrants		473		-			-		-		(113	)		360
	$	2,054	$	(307	)	$	331	$	-	$	1,409		$	3,487

(1) Royalty payments of $307,000 are reflected within Cash Flows from Operations.